tiprankstipranks
Trending News
More News >
Beyond Air Inc (XAIR)
NASDAQ:XAIR
Advertisement

Beyond Air (XAIR) AI Stock Analysis

Compare
627 Followers

Top Page

XAIR

Beyond Air

(NASDAQ:XAIR)

Rating:49Neutral
Price Target:
$2.00
▼(-7.83% Downside)
Beyond Air's stock score is primarily influenced by its financial performance challenges, including negative profitability and cash flow issues. While the earnings call and corporate events provide some optimism with revenue growth and strategic initiatives, the technical analysis and valuation remain weak, reflecting bearish momentum and ongoing losses.
Positive Factors
Market Expansion
With newly signed distribution agreements in ex-U.S. markets, XAIR has access to over 30 countries.
Product Approval
Approval of the second generation LungFit PH system is expected to drive substantial revenue growth and market adoption.
Sales Momentum
The company is gaining sales momentum and reiterated fiscal year 2026 guidance of $12M - $16M.
Negative Factors
Cash Position Concerns
The sustained negative pressure on the stock is being driven primarily by concerns over the company's cash position.
Delayed Revenue Achievement
Beyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue due to delays and disruptions during the COVID-19 pandemic and a failed agreement with a partner.
Initial Commercial Challenges
Beyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue.

Beyond Air (XAIR) vs. SPDR S&P 500 ETF (SPY)

Beyond Air Business Overview & Revenue Model

Company DescriptionBeyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
How the Company Makes MoneyBeyond Air generates revenue primarily through the sale of its proprietary nitric oxide delivery systems and related products. The company's key revenue streams include direct sales of its devices to hospitals and healthcare providers, as well as potential licensing agreements for its technologies. Additionally, Beyond Air may benefit from partnerships with pharmaceutical companies for the development of combination therapies. The ongoing commercialization of its products and the expansion into new markets are critical factors contributing to its earnings, alongside potential reimbursement strategies with healthcare payers.

Beyond Air Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The earnings call reflected strong financial performance with substantial revenue growth, cost reduction, and international expansion. However, the company faces ongoing net losses and challenges in scaling international sales promptly. The sentiment is cautiously optimistic with positive growth indicators.
Q1-2026 Updates
Positive Updates
Significant Revenue Growth
Beyond Air reported a 157% increase in revenue for Q1 fiscal year 2026, reaching $1.8 million compared to $700,000 in the same period last year, and a 50% sequential increase from the previous quarter.
Cost Reduction Success
Operating expenses were reduced by 40% year-over-year to just above $7.5 million in the June quarter from $13 million for the same period last year.
International Expansion
First quarter of international revenues recorded with distribution partners covering more than 30 countries and over 2 billion lives.
Cash Burn Reduction
Net cash burn for the quarter was $4.7 million, more than 60% lower than the first quarter of the last fiscal year.
FDA Compliance
Beyond Air regained compliance with Nasdaq listing rules following a 1-for-20 reverse stock split.
Negative Updates
Net Loss Continues
Net loss attributed to common stockholders was $7.7 million or a loss of $1.53 per share.
Challenges in Scaling International Sales
Revenues from international operations are currently only from demonstration devices and training devices, with significant sales expected only towards the end of the fiscal year.
Company Guidance
During the Beyond Air Financial Results Call for the first fiscal quarter of 2026, the company reported a remarkable 157% year-over-year increase in revenue, reaching $1.8 million compared to the previous year's $700,000. This growth was driven by the continued market adoption of LungFit PH, reflecting a sequential 50% revenue increase from the previous quarter. The company also noted a significant reduction in operating expenses, which decreased to $7.5 million from $13 million the previous year, marking a 40% year-over-year reduction. Beyond Air reaffirmed its revenue guidance for fiscal year 2026, projecting a range of $12 million to $16 million. The company has expanded its international presence, now having access to over 30 countries through distribution partners, and has secured a national group purchasing agreement with Premier, providing access to nearly 3,000 hospitals. Additionally, Beyond Air reported a net loss of $7.7 million for the quarter, a reduction from the $12.2 million loss in the same period last year, and its net cash burn decreased by more than 60% year-over-year.

Beyond Air Financial Statement Overview

Summary
Beyond Air is in a growth phase with increasing revenues but faces significant profitability and cash flow challenges. The company exhibits a stable financial structure with low leverage, yet it struggles with negative margins and cash flows. Strategic improvements in cost management and operational efficiency are crucial for enhancing profitability and ensuring sustainable growth.
Income Statement
35
Negative
Beyond Air's income statement reveals significant challenges. The company has experienced a substantial revenue growth rate of 29.07% in the TTM, indicating potential market traction. However, profitability remains a concern with negative gross profit, net profit, and EBIT margins, reflecting ongoing operational inefficiencies and high costs relative to revenue. The consistent negative margins highlight the need for strategic cost management and revenue enhancement.
Balance Sheet
45
Neutral
The balance sheet shows a relatively low debt-to-equity ratio of 0.21 in the TTM, suggesting manageable leverage levels. However, the return on equity is significantly negative, indicating that the company is not generating sufficient returns on shareholder investments. The equity ratio stands at 35.31%, showing a moderate reliance on equity financing. Overall, the balance sheet reflects a stable financial structure but with poor profitability metrics.
Cash Flow
40
Negative
Cash flow analysis indicates a challenging environment with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with reported losses. However, the negative free cash flow growth rate of -18.43% in the TTM highlights deteriorating cash generation capabilities. The company needs to improve its cash flow management to support its operations and growth.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.78M3.71M1.16M0.000.00873.00K
Gross Profit-1.18M-1.66M-1.31M-555.00K-588.00K873.00K
EBITDA-37.23M-41.89M-59.03M-58.20M-42.70M-22.02M
Net Income-42.12M-46.63M-60.24M-55.82M-43.18M-22.88M
Balance Sheet
Total Assets28.11M30.06M56.96M68.75M99.20M40.52M
Cash, Cash Equivalents and Short-Term Investments6.63M6.92M34.47M45.88M80.24M34.63M
Total Debt11.69M11.69M17.84M3.59M3.49M6.93M
Total Liabilities17.71M15.72M29.77M26.72M20.99M10.06M
Stockholders Equity9.93M13.58M25.05M37.91M72.70M30.46M
Cash Flow
Free Cash Flow-35.97M-44.10M-61.76M-36.89M-24.58M-20.53M
Operating Cash Flow-32.56M-38.22M-56.01M-33.01M-23.13M-19.64M
Investing Cash Flow12.37M14.90M-12.23M-20.59M-1.45M-890.00K
Financing Cash Flow20.98M16.65M43.17M2.70M79.45M30.33M

Beyond Air Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.17
Price Trends
50DMA
2.96
Negative
100DMA
3.48
Negative
200DMA
5.52
Negative
Market Momentum
MACD
-0.23
Negative
RSI
36.79
Neutral
STOCH
59.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Negative. The current price of 2.17 is below the 20-day moving average (MA) of 2.41, below the 50-day MA of 2.96, and below the 200-day MA of 5.52, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 36.79 is Neutral, neither overbought nor oversold. The STOCH value of 59.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XAIR.

Beyond Air Risk Analysis

Beyond Air disclosed 73 risk factors in its most recent earnings report. Beyond Air reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Beyond Air Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$97.80M12.685.00%0.29%-22.13%
60
Neutral
$219.03M-13.46%5.15%73.29%
58
Neutral
$55.57M48.68-1.62%3.30%-112.70%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
49
Neutral
$11.55M-323.27%168.20%63.41%
44
Neutral
$70.49M-66.88%18.24%4.81%
40
Underperform
$241.02M-32.87%17.36%9.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XAIR
Beyond Air
2.17
-6.03
-73.54%
FONR
Fonar
15.65
-0.84
-5.09%
INGN
Inogen
8.12
-3.18
-28.14%
SRTS
Sensus Healthcare
3.18
-2.34
-42.39%
NNOX
Nano-X Imaging
3.72
-2.18
-36.95%
LUNG
Pulmonx
1.74
-5.57
-76.20%

Beyond Air Corporate Events

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Beyond Air Implements Reverse Stock Split for Nasdaq Compliance
Neutral
Jul 10, 2025

Beyond Air, Inc. announced a 1-for-20 reverse stock split of its common stock, approved during a special stockholders meeting on June 20, 2025, and effective on July 14, 2025. This move aims to increase the per share bid price above $1.00 to comply with Nasdaq Listing Rule 5550(a)(2). While the reverse stock split will adjust the number of shares held by stockholders, it will not affect the company’s authorized capital stock or the rights of preferred stockholders. The company hopes this action will help regain compliance with Nasdaq requirements, although there is no assurance of achieving the desired effects.

Shareholder MeetingsStock Split
Beyond Air Approves Reverse Stock Split Proposal
Neutral
Jun 25, 2025

On June 20, 2025, Beyond Air, Inc. held a special meeting of stockholders where a reverse stock split proposal was approved. The proposal grants the board of directors the authority to implement a reverse stock split at a ratio between 1-for-10 and 1-for-50 within a year, potentially impacting the company’s stock structure and market perception.

Executive/Board ChangesBusiness Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Beyond Air Appoints Robert Goodman to Board
Positive
Jun 18, 2025

On June 16, 2025, Beyond Air appointed Robert Goodman to its Board of Directors, bringing his extensive experience in healthcare leadership to the company. Additionally, Beyond Air announced the submission of a premarket approval supplement to the FDA for its second-generation LungFit PH device, which could significantly enhance its market potential. The company reported a 220% increase in annual revenue for the fiscal year ending March 31, 2025, driven by the demand for LungFit PH and international expansion. Despite a net loss, Beyond Air’s strategic moves, including new distribution partnerships and regulatory approvals, position it for a pivotal year ahead.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025